Saxo's Peter Garnry says the catalyst has been weaker investment sentiment plus discussions by, among others, Hillary Clinton, on drug price caps. He says investors need to know that there will be an appropriate return on capital, which is under threat from on-going uncertainty.

Peter is still positive on the sector and cites two companies in particular - Gilead Sciences and Biogen - which he says offer attractive long term opportunities.